Nirsevimab-A Breakthrough in Respiratory Syncytial Virus Bronchiolitis

• 2024

  Log in to bookmark this resource.

  Log in
• Zein Assad; Jesse Papenburg; Naïm Ouldali
PMID: 39208834DOI: https://dx.doi.org/10.1016/S2352-4642(24)00228-1

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

This article comments on immunization programs with nirsevimab that began in 2023 in some countries like France, with its impact being studied in recent publications. It highlights the potential of nirsevimab as a significant advancement in treating respiratory syncytial virus (RSV) bronchiolitis. It describes how nirsevimab could reduce hospitalizations and severe cases of RSV in children.

---

Tags

Focus Area: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundle: Nirsevimab Library

Keywords: Antiviral Agents; Bronchiolitis; France; Infant; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Palivizumab; Antibodies, Monoclonal, Humanized

Institutions: Paris Cité University; McGill University

---

More like this

Nirsevimab-A Breakthrough in Respiratory Syncytial Virus Bronchiolitis 2024 · Paris Cité University, McGill University The Assessment of Future RSV Immunizations: How to Protect All Infants? 2022 · University Medical Centre Utrecht, Paris Cité University, University of Lübeck, University of Parma, Comunidad de Madrid, Università Degli Studi Di Milano Statale, European Foundation for the Care of Newborn Infants (EFCNI), Nihon University School of Medicine, Beijing Children's Hospital, University of Thessaly, University of Southampton, University Hospital Southampton NHS Foundation Trust, Bambino Gesù Children Hospital Immunization Technologies: Time to Consider New Preventative Solutions for Respiratory Syncytial Virus Infections 2023 · Paris Cité University, Chatham House, Spanish Association of Vaccinology, Chinese Center for Disease Control and Prevention, University of Parma, Sapienza Università di Roma, Charité – Universitätsmedizin Berlin

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---